Phytopharm Gets FDA Nod To Commence Cogane Phase II Clinical Trial
The study is expected to evaluate the efficacy, safety and tolerability of Cogane, administered for 28 weeks to patients with early stage Parkinson’s disease. The primary endpoint for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.